New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2013
08:24 EDTSLXPSalix price target raised to $60 from $54 at Roth Capital
Roth Capital increased its price target on Salix after the company reported higher than expected Q4 EPS. The firm believes that the company's Xifaxan drug is beating expectations and it maintains a Buy rating on the shares.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
17:19 EDTSLXPCNO Financial to replace Salix Pharmaceuticals in S&P 400 as of 4/6 close
Subscribe for More Information
16:27 EDTSLXPSalix Pharmaceuticals requests withdrawal of registration statement
Subscribe for More Information
06:07 EDTSLXPValeant completes tender offer for Salix
Subscribe for More Information
06:05 EDTSLXPValeant Pharmaceuticals International completes tender offer for Salix
Subscribe for More Information
March 26, 2015
10:45 EDTSLXPSynergy discussing possible sale with advisers, Bloomberg reports
Subscribe for More Information
March 25, 2015
12:58 EDTSLXPPershing Square raises stake in Valeant, says will discuss acquisitions
Subscribe for More Information
10:51 EDTSLXPOptions with increasing implied volatility
Options with increasing implied volatility: CLDN CMG CREE AMZN ISRG MAC UA VMW SLXP
March 20, 2015
16:33 EDTSLXPStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
10:18 EDTSLXPOptions with decreasing implied volatility
Options with decreasing implied volatility: NKTR FOLD RUSL RSX ORCL GES CTRP SLXP WSM SPXS
March 19, 2015
10:42 EDTSLXPOptions with decreasing implied volatility
Subscribe for More Information
March 18, 2015
10:00 EDTSLXPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:45 EDTSLXPSalix downgraded to Hold from Buy at Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use